Phase 1 imaging has been completed on 33 patients with Technetium-99m in Shanghai and Germany
Non-invasive and demonstrated safety
Accumulation / high uptake in target within 2 hours post injection
Acceptable biodistribution and dosimetry (renal protection can be achieved by standard pre-injection of gelufusin/amino acids mixture)
Shows clear intra and inter-tumoural heterogeneity of HER-2 expression
Provide more accurate and informative information on HER-2 cancers in comparison to existing IHC / FISH detections from biopsy samples
Potential to be used for whole body assessment and treatment of HER-2+ cancers with different medical radioisotopes
HER-2 PHASE 1 BREAST THERAPEUTIC COMMENCING
Phase 1 therapeutic about to launch in late stage HER-2+ breast cancer in Germany with Re-188 and Lu-177
Can be easily adopted as a therapeutic with Lu-177 or Ac-225
High probability of success as a therapeutic agent
Patient safety data
Same targeting as imaging but just change of war-head ( Tc-99m to Re-188, or Ga-68 to Lu-177 )
Re- and Tc- structural and reaction chemistry is the “same” – easy conversion
Apply to patients with good images and dosimetry – see then treat
PD-L1 PHASE 1 NON SMALL CELL LUNG CANCER IMAGING HAS BEEN COMPLETED ON 40 PATIENTS
PD-L1 is a pan-cancer biomarker and immuno-checkpoint blockers are becoming the most important treatment of multiple cancers
Imaging technology is licensed to Lantheus for research collaborations in diagnostic imaging
Worldwide exclusive license to Radioharm Theranostics for therapeutic use
Imaging done on 40 NSCLC patients in Shanghai General and at Kings College London
Approved for Phase 2 Imaging Clinical Trial by MHRA
DMF for Imaging filed with FDA in US
Easily adopted for therapeutic use
High probability of success as therapeutic agent
Patients safety data; same cold kit as imaging but just change of war-head
Apply to patients with good images – see then treat
Pivalate Clinical Trials
Pivalate Phase 1
Imaging complete in cerebral metastases, glioma, kidney, solid tumors
Pivalate Phase 2
In cerebral metastases, glioma interim positive data summary below
AVβ6 Integrin Clinical Trials
AVβ6 BEST-IN-CLASS : PHASE 1a COMMENCED
Biodistribution generally (Healthy subject comparison)
*None of Radiopharm Theranositcs’ product pipeline has received marketing authorization in any jurisdiction. Any use of Radiopharm Theranostic products is on an investigational basis or for use in approved clinical trials.
Sign up to our mailing list.
Receive all the latest news from Radiopharm Theranostics.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form. Please fill out all starred fields.